Kaleidospace - KSPACE

Cool vaccines in rural Kenya: Solar solution has been awarded by UN In May 2026, Tabitha Awuor Amollo is spending some weeks as a guest scientist at HZB, analysing perovskite thin films at BESSY II. The Kenyan physicist from Egerton University, Nairobi, was recently recognised for her achievements in research and teaching. For the development of a solar-powered refr...

The freedom to create, innovate, and share our worlds with others across the globe is a gift we don't take for granted. Today, we honor the brave individuals who laid down their lives in service to our country. We remember—today and every day.

An early-stage clinical trial co-led by Washington University in St. Louis has found that a personalized DNA cancer vaccine designed to target up to 40 unique tumor proteins stimulates an immune response against aggressive glioblastoma brain tumors. By transforming “cold” tumors into targets visible to the body’s immune system, the vaccine successfully doubled historical survival rates for a subset of participants – with one patient remaining completely recurrence-free nearly 5 years after surgery.

– WashU Medicine's Mark Reynolds

Personalized vaccine shows promise against aggressive brain cancer | WashU Medicine A WashU Medicine-led clinical trial has found that a personalized vaccine to treat glioblastoma appears to increase recurrence-free survival in a subset of patients after surgery.